The stock of Plus Therapeutics Inc (PSTV) has gone down by -40.70% for the week, with a -45.11% drop in the past month and a -84.22% drop in the past quarter. The volatility ratio for the week is 20.14%, and the volatility levels for the past 30 days are 12.15% for PSTV. The simple moving average for the last 20 days is -38.67% for PSTV’s stock, with a simple moving average of -82.13% for the last 200 days.
Is It Worth Investing in Plus Therapeutics Inc (NASDAQ: PSTV) Right Now?
PSTV has 36-month beta value of 0.63. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PSTV is 29.81M, and currently, short sellers hold a 1.72% ratio of that float. The average trading volume of PSTV on June 23, 2025 was 7.72M shares.
PSTV) stock’s latest price update
The stock price of Plus Therapeutics Inc (NASDAQ: PSTV) has jumped by 2453910 compared to previous close of 0.19. Despite this, the company has seen a fall of -40.70% in its stock price over the last five trading days. zacks.com reported 2025-06-19 that Plus (PSTV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Analysts’ Opinion of PSTV
Many brokerage firms have already submitted their reports for PSTV stocks, with D. Boral Capital repeating the rating for PSTV by listing it as a “Buy.” The predicted price for PSTV in the upcoming period, according to D. Boral Capital is $9 based on the research report published on March 17, 2025 of the current year 2025.
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see PSTV reach a price target of $8. The rating they have provided for PSTV stocks is “Buy” according to the report published on January 25th, 2021.
Maxim Group gave a rating of “Buy” to PSTV, setting the target price at $6 in the report published on October 16th of the previous year.
PSTV Trading at -62.71% from the 50-Day Moving Average
After a stumble in the market that brought PSTV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.94% of loss for the given period.
Insider Trading
Hawkins Richard J, the Director of Plus Therapeutics Inc, purchase 4,000 shares at $1.50 during a trade that took place back on Sep 13 ’24, which means that Hawkins Richard J is holding 15,188 shares at $5,996 based on the most recent closing price.
Stock Fundamentals for PSTV
Current profitability levels for the company are sitting at:
- -11.67 for the present operating margin
- -1.17 for the gross margin
The net margin for Plus Therapeutics Inc stands at -21.2. The total capital return value is set at -9.97.
Based on Plus Therapeutics Inc (PSTV), the company’s capital structure generated -0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -305.32. The debt to equity ratio resting at -0.0. The interest coverage ratio of the stock is -3.82.
Currently, EBITDA for the company is -8.4 million with net debt to EBITDA at 0.44. When we switch over and look at the enterprise to sales, we see a ratio of -2.89. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.99.
Conclusion
To put it simply, Plus Therapeutics Inc (PSTV) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
